Literature DB >> 30541238

Is 72 h of antimicrobial prophylaxis better than 24 h in elective gastric cancer surgery?

Xiang Xia1, Gang Zhao1, Wei Ling1, Fengrong Yu1.   

Abstract

Background/aim: The optimum duration of antimicrobial prophylaxis in elective gastric cancer surgery is still not yet established. The aim of this study is to evaluate the efficacy of 24 h or 72 h of antimicrobial prophylaxis for preventing postoperative infection. Materials and methods: Between July 2016 and January 2018, 990 gastric cancer patients undergoing surgery with D2 lymphadenectomy in Ren Ji Hospital were classified into 24-h or 72-h antimicrobial prophylaxis groups. The incidence of postoperative infection complications was compared.
Results: A total of 990 patients (24-h antimicrobial prophylaxis, 708 cases; 72-h antimicrobial prophylaxis, 282 cases) were analyzed. Surgical site infection (SSI) occurred in 37 patients (5.2%) in the 24-h group and 17 patients (6.0%) in the 72-h group, respectively, and 24-h antimicrobial prophylaxis was not a risk factor for remote infection (11.2% in 24-h versus 10.2% in 72-h group). Age >60 years and pathological stage III were significantly associated with remote infection.
Conclusion: Compared to 72 h of antimicrobial prophylaxis, 24 h is not a risk factor for either SSI or remote infection. Extended antimicr obial prophylaxis might decrease remote infections for older patients or those of pathological stage III. This work is licensed under a Creative Commons Attribution 4.0 International License.

Entities:  

Keywords:  Gastric cancer; antimicrobial prophylaxis; surgical site infection; remote infection

Year:  2018        PMID: 30541238     DOI: 10.3906/sag-1804-1

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  1 in total

1.  Neutrophil extracellular traps promote metastasis in gastric cancer patients with postoperative abdominal infectious complications.

Authors:  Xiang Xia; Zizhen Zhang; Chunchao Zhu; Bo Ni; Shuchang Wang; Shuofei Yang; Fengrong Yu; Enhao Zhao; Qing Li; Gang Zhao
Journal:  Nat Commun       Date:  2022-02-23       Impact factor: 14.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.